Biotech exec Jeremy Levin on the industry’s strategic turning point
-
By
-
Adam Feuerstein
-
Allison DeAngelis
-
Elaine Chen
-
May 28, 2026
-
Clinical Scorecard: Jeremy Levin Discusses a Pivotal Moment for the Biotech Sector
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Biotech sector stakeholders and patients with high cholesterol |
| Care Setting | |
Key Highlights
- Discussion of Jeremy Levin's new book on the biotech industry
- Recap of Eli Lilly's gene-editing treatment for high cholesterol and its implications
- New funding for a longevity startup
- Preview of the upcoming ASCO cancer research meeting and its significance
Guideline-Based Recommendations
Diagnosis
- Consider genetic testing for high cholesterol
Management
- Lifestyle changes and potential gene-editing treatments
Monitoring & Follow-up
- Regular lipid profile assessments
Risks
- Potential side effects of gene-editing treatments
Patient & Prescribing Data
Patients with high cholesterol
Eli Lilly's gene-editing treatment
Clinical Best Practices
- Incorporate gene-editing treatments into patient care plans where applicable
Related Resources & Content
